New Overweight Rating Was Given to uniQure (QURE)

July 27, 2018 - By Pearl Odom

uniQure N.V. (NASDAQ:QURE) Logo

Why Has Cantor Fitzgerald Given uniQure (QURE) a $58.0 Price Target

In an analyst report revealed to clients and investors on Friday, 27 July, research analysts at Cantor Fitzgerald has begun coverage for uniQure (QURE) shares. The firm has decided to set a Overweight rating along with a $58.0, adding 81.48 % to the target.

The stock decreased 1.36% or $0.44 during the last trading session, reaching $31.96. About 303,159 shares traded. uniQure N.V. (QURE) has risen 534.87% since July 27, 2017 and is uptrending. It has outperformed by 522.30% the S&P500.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on August, 14. They expect $-0.62 earnings per share, up 25.30 % or $0.21 from last year’s $-0.83 per share. After $-0.59 actual earnings per share reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 5.08 % negative EPS growth.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.18 billion. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Nasdaq.com which released: “uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B” on June 28, 2018, also Benzinga.com with their article: “40 Biggest Movers From Yesterday” published on July 17, 2018, Benzinga.com published: “3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy” on June 29, 2018. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Streetinsider.com and their article: “UPDATE: Cantor Fitzgerald Starts uniQure BV (QURE) at Overweight” published on July 26, 2018 as well as Seekingalpha.com‘s news article titled: “uniQure: Buy The Dip” with publication date: July 26, 2018.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.